Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390 | 0.95 | TSHR (0.43) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL30753199 | 0.95 | TSHR (0.43) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL8257796 | 0.88 | TSHR (0.47) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL5461436 | 0.88 | HTT (0.41) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL690412 | 0.86 | POLB (0.46) | TSHRSMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL30204393 | 0.86 | GPR27 (0.41) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL29997409 | 0.86 | POLB (0.46) | TSHRSMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL4949499 | 0.86 | GPR27 (0.41) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL8282300 | 0.86 | TSHR (0.39) | TSHRSMN1; SMN2ALDH1A1CES2CES1 | |
| SCHEMBL15495179 | 0.85 | ALOX15 (0.47) | TSHRSMN1; SMN2ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119812479-A | Electrolyte matched with high-voltage lithium metal battery and preparation method thereof | 新乡华锐锂电新能源股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119812479-B | Electrolyte matched with high-voltage lithium metal battery and preparation method thereof | 新乡华锐锂电新能源股份有限公司 | 2025-06-06 | — | — | CN | disclosed |
| CN-119812479-A | Electrolyte matched with high-voltage lithium metal battery and preparation method thereof | 新乡华锐锂电新能源股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119812479-A | Electrolyte matched with high-voltage lithium metal battery and preparation method thereof | 新乡华锐锂电新能源股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | TSHR 2281/4885SMN1; SMN2 208/4885ALDH1A1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.